FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366239802> ?p ?o ?g. }

• W4366239802 endingPage "1669" @default.
• W4366239802 startingPage "1654" @default.
• W4366239802 abstract "Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of action remains elusive. Derangements in myocardial energy metabolism are detectable in all HF phenotypes, and it was proposed that SGLT2i may improve energy production. The authors aimed to investigate whether treatment with empagliflozin leads to changes in myocardial energetics, serum metabolomics, and cardiorespiratory fitness.EMPA-VISION (Assessment of Cardiac Energy Metabolism, Function and Physiology in Patients With Heart Failure Taking Empagliflozin) is a prospective, randomized, double-blind, placebo-controlled, mechanistic trial that enrolled 72 symptomatic patients with chronic HF with reduced ejection fraction (HFrEF; n=36; left ventricular ejection fraction ≤40%; New York Heart Association class ≥II; NT-proBNP [N-terminal pro-B-type natriuretic peptide] ≥125 pg/mL) and HF with preserved ejection fraction (HFpEF; n=36; left ventricular ejection fraction ≥50%; New York Heart Association class ≥II; NT-proBNP ≥125 pg/mL). Patients were stratified into respective cohorts (HFrEF versus HFpEF) and randomly assigned to empagliflozin (10 mg; n=35: 17 HFrEF and 18 HFpEF) or placebo (n=37: 19 HFrEF and 18 HFpEF) once daily for 12 weeks. The primary end point was a change in the cardiac phosphocreatine:ATP ratio (PCr/ATP) from baseline to week 12, determined by phosphorus magnetic resonance spectroscopy at rest and during peak dobutamine stress (65% of age-maximum heart rate). Mass spectrometry on a targeted set of 19 metabolites was performed at baseline and after treatment. Other exploratory end points were investigated.Empagliflozin treatment did not change cardiac energetics (ie, PCr/ATP) at rest in HFrEF (adjusted mean treatment difference [empagliflozin - placebo], -0.25 [95% CI, -0.58 to 0.09]; P=0.14) or HFpEF (adjusted mean treatment difference, -0.16 [95% CI, -0.60 to 0.29]; P=0.47]. Likewise, there were no changes in PCr/ATP during dobutamine stress in HFrEF (adjusted mean treatment difference, -0.13 [95% CI, -0.35 to 0.09]; P=0.23) or HFpEF (adjusted mean treatment difference, -0.22 [95% CI, -0.66 to 0.23]; P=0.32). No changes in serum metabolomics or levels of circulating ketone bodies were observed.In patients with either HFrEF or HFpEF, treatment with 10 mg of empagliflozin once daily for 12 weeks did not improve cardiac energetics or change circulating serum metabolites associated with energy metabolism when compared with placebo. Based on our results, it is unlikely that enhancing cardiac energy metabolism mediates the beneficial effects of SGLT2i in HF.URL: https://www.gov; Unique identifier: NCT03332212." @default.
• W4366239802 created "2023-04-20" @default.
• W4366239802 creator A5000096387 @default.
• W4366239802 creator A5000787488 @default.
• W4366239802 creator A5007720638 @default.
• W4366239802 creator A5017025108 @default.
• W4366239802 creator A5019886336 @default.
• W4366239802 creator A5026356825 @default.
• W4366239802 creator A5026575926 @default.
• W4366239802 creator A5030207119 @default.
• W4366239802 creator A5033753375 @default.
• W4366239802 creator A5033848873 @default.
• W4366239802 creator A5038084660 @default.
• W4366239802 creator A5049740900 @default.
• W4366239802 creator A5059279475 @default.
• W4366239802 creator A5064980874 @default.
• W4366239802 creator A5072206027 @default.
• W4366239802 creator A5076713788 @default.
• W4366239802 creator A5076795620 @default.
• W4366239802 creator A5080912918 @default.
• W4366239802 creator A5082858471 @default.
• W4366239802 creator A5086162952 @default.
• W4366239802 creator A5086239114 @default.
• W4366239802 date "2023-05-30" @default.
• W4366239802 modified "2023-10-05" @default.
• W4366239802 title "Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial" @default.
• W4366239802 cites W1943654307 @default.
• W4366239802 cites W1983059887 @default.
• W4366239802 cites W2005511622 @default.
• W4366239802 cites W2016431737 @default.
• W4366239802 cites W2065231082 @default.
• W4366239802 cites W2069496858 @default.
• W4366239802 cites W2081133653 @default.
• W4366239802 cites W2086828019 @default.
• W4366239802 cites W2094648371 @default.
• W4366239802 cites W2099925531 @default.
• W4366239802 cites W2102780353 @default.
• W4366239802 cites W2107567775 @default.
• W4366239802 cites W2132146459 @default.
• W4366239802 cites W2146264128 @default.
• W4366239802 cites W2157405334 @default.
• W4366239802 cites W2167942713 @default.
• W4366239802 cites W2253712555 @default.
• W4366239802 cites W2273304042 @default.
• W4366239802 cites W2412800896 @default.
• W4366239802 cites W2611066427 @default.
• W4366239802 cites W2664551728 @default.
• W4366239802 cites W2745294544 @default.
• W4366239802 cites W2759916106 @default.
• W4366239802 cites W2790321432 @default.
• W4366239802 cites W2790822079 @default.
• W4366239802 cites W2792450684 @default.
• W4366239802 cites W2888544493 @default.
• W4366239802 cites W2889590224 @default.
• W4366239802 cites W2894915660 @default.
• W4366239802 cites W2925036255 @default.
• W4366239802 cites W2943788550 @default.
• W4366239802 cites W2953473968 @default.
• W4366239802 cites W2969482818 @default.
• W4366239802 cites W2974260792 @default.
• W4366239802 cites W2985962366 @default.
• W4366239802 cites W2989060738 @default.
• W4366239802 cites W3081830235 @default.
• W4366239802 cites W3092932642 @default.
• W4366239802 cites W3100542962 @default.
• W4366239802 cites W3101357080 @default.
• W4366239802 cites W3102766101 @default.
• W4366239802 cites W3118491390 @default.
• W4366239802 cites W3118652086 @default.
• W4366239802 cites W3129290046 @default.
• W4366239802 cites W3134467673 @default.
• W4366239802 cites W3157301626 @default.
• W4366239802 cites W3193598686 @default.
• W4366239802 cites W3203350643 @default.
• W4366239802 cites W4206498374 @default.
• W4366239802 cites W4225396975 @default.
• W4366239802 cites W4226396866 @default.
• W4366239802 cites W4253111054 @default.
• W4366239802 cites W4281295871 @default.
• W4366239802 cites W4285259396 @default.
• W4366239802 cites W4293447102 @default.
• W4366239802 cites W4322720015 @default.
• W4366239802 doi "https://doi.org/10.1161/circulationaha.122.062021" @default.
• W4366239802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37070436" @default.
• W4366239802 hasPublicationYear "2023" @default.
• W4366239802 type Work @default.
• W4366239802 citedByCount "7" @default.
• W4366239802 countsByYear W43662398022023 @default.
• W4366239802 crossrefType "journal-article" @default.
• W4366239802 hasAuthorship W4366239802A5000096387 @default.
• W4366239802 hasAuthorship W4366239802A5000787488 @default.
• W4366239802 hasAuthorship W4366239802A5007720638 @default.
• W4366239802 hasAuthorship W4366239802A5017025108 @default.
• W4366239802 hasAuthorship W4366239802A5019886336 @default.
• W4366239802 hasAuthorship W4366239802A5026356825 @default.
• W4366239802 hasAuthorship W4366239802A5026575926 @default.
• W4366239802 hasAuthorship W4366239802A5030207119 @default.
• W4366239802 hasAuthorship W4366239802A5033753375 @default.

• next